Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program
Anne‐Marie Duliège(Sunesis (United States)), James B. Bussel(Cornell University), Darla Liles(University of North Carolina at Chapel Hill), Quentin A. Hill(Leeds Teaching Hospitals NHS Trust), Sandra Tong(Rigel (United States)), Michael Boxer(Arizona Oncology), Michelle Sholzberg(St. Michael's Hospital), Hany Zayed(King's College London), Nichola Cooper(Imperial College London), Ralph V. Boccia(Center for Cancer and Blood Disorders), Donald M. Arnold(McMaster University)
Cited by 12
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
|Modern Pathology|2020|478